Completed PHASE2 INTERVENTIONAL 3-arm NCT00542919

A Study for Patients With Non-Hodgkin's Lymphomas

A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas

Sponsor: Eli Lilly and Company

Conditions B-Cell Lymphoma T-Cell Lymphoma

Interventions enzastaurin

Updated 9 times since 2017 Last updated: Sep 23, 2020 Started: Nov 30, 2007 Primary completion: Mar 31, 2010 Completion: Feb 27, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates B-Cell Lymphoma and T-Cell Lymphoma and is currently completed. Eli Lilly and Company leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — May 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Auchenflower, Australia , Brasília, Brazil , Curitiba, Brazil , Garran, Australia , Gosford, Australia , Jaú, Brazil , Lima, Peru , Monterrey, Mexico , Porto Alegre, Brazil and 4 more locations